CPRX logo

Catalyst Pharmaceuticals (CPRX) Stock

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

08 November 2006

Indexes:

Not included

Description:

Catalyst Pharmaceuticals (CPRX) is a biopharmaceutical company focused on developing and commercializing treatments for rare neurological diseases. They aim to improve the lives of patients with conditions like Lambert-Eaton Myasthenic Syndrome (LEMS) through innovative therapies and strong partnerships in the healthcare industry.

Key Details

Price

$22.25

Annual Revenue

$398.20 M(+85.90% YoY)

Annual EPS

$0.63(-16.00% YoY)

PE Ratio

18.86(-29.84% YoY)

Beta

1.29

Events Calendar

Earnings

Next earnings date:

Feb 28, 2025

Recent quarterly earnings:

Nov 07, 2024

Recent annual earnings:

Feb 28, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

18 Nov '24 Stephens & Co.
Overweight
11 Nov '24 Truist Securities
Buy
08 Nov '24 HC Wainwright & Co.
Buy
12 Aug '24 HC Wainwright & Co.
Buy
09 Aug '24 Truist Securities
Buy
09 Aug '24 Citigroup
Buy
06 June '24 Oppenheimer
Outperform
03 June '24 HC Wainwright & Co.
Buy
10 May '24 HC Wainwright & Co.
Buy
27 Mar '24 Oppenheimer
Outperform

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Momentum Stock
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Momentum Stock
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Momentum Stock
CPRX
zacks.com27 November 2024

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences
Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences
Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences
CPRX
globenewswire.com19 November 2024

CORAL GABLES, Fla., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Richard J. Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will participate in the upcoming investor conferences detailed below.

Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock
CPRX
zacks.com15 November 2024

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Catalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to Work
Catalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to Work
Catalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to Work
CPRX
globenewswire.com13 November 2024

CORAL GABLES, Fla., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it has been named on the BioSpace 2025 Best Places to Work. Catalyst is among 50 U.S. operating employers on the Best Places to Work list. The recipients are recognized as the most sought-after in the industry by the life sciences community.

CPRX Q3 Earnings & Revenues Beat Estimates, '24 View Raised, Stock Up
CPRX Q3 Earnings & Revenues Beat Estimates, '24 View Raised, Stock Up
CPRX Q3 Earnings & Revenues Beat Estimates, '24 View Raised, Stock Up
CPRX
zacks.com07 November 2024

Catalyst stock gains on strong third-quarter results, beating earnings and revenue estimates, primarily driven by Firdapse sales. Management raises sales guidance.

CPRX vs. STVN: Which Stock Is the Better Value Option?
CPRX vs. STVN: Which Stock Is the Better Value Option?
CPRX vs. STVN: Which Stock Is the Better Value Option?
CPRX
zacks.com06 November 2024

Investors with an interest in Medical - Drugs stocks have likely encountered both Catalyst Pharmaceutical (CPRX) and Stevanato Group (STVN). But which of these two companies is the best option for those looking for undervalued stocks?

Catalyst Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 6, 2024
Catalyst Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 6, 2024
Catalyst Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 6, 2024
CPRX
globenewswire.com22 October 2024

The Company will Host a Conference Call and Webcast on Thursday, November 7, 2024, at 8:30 AM ET The Company will Host a Conference Call and Webcast on Thursday, November 7, 2024, at 8:30 AM ET

CPRX or STVN: Which Is the Better Value Stock Right Now?
CPRX or STVN: Which Is the Better Value Stock Right Now?
CPRX or STVN: Which Is the Better Value Stock Right Now?
CPRX
zacks.com21 October 2024

Investors interested in stocks from the Medical - Drugs sector have probably already heard of Catalyst Pharmaceutical (CPRX) and Stevanato Group (STVN). But which of these two stocks presents investors with the better value opportunity right now?

New Strong Buy Stocks for October 8th
New Strong Buy Stocks for October 8th
New Strong Buy Stocks for October 8th
CPRX
zacks.com08 October 2024

CPRX, HCI, DXC, CRAI and CRUS have been added to the Zacks Rank #1 (Strong Buy) List on October 8, 2024.

CPRX or STVN: Which Is the Better Value Stock Right Now?
CPRX or STVN: Which Is the Better Value Stock Right Now?
CPRX or STVN: Which Is the Better Value Stock Right Now?
CPRX
zacks.com04 October 2024

Investors interested in Medical - Drugs stocks are likely familiar with Catalyst Pharmaceutical (CPRX) and Stevanato Group (STVN). But which of these two stocks is more attractive to value investors?

FAQ

  • What is the primary business of Catalyst Pharmaceuticals?
  • What is the ticker symbol for Catalyst Pharmaceuticals?
  • Does Catalyst Pharmaceuticals pay dividends?
  • What sector is Catalyst Pharmaceuticals in?
  • What industry is Catalyst Pharmaceuticals in?
  • What country is Catalyst Pharmaceuticals based in?
  • When did Catalyst Pharmaceuticals go public?
  • Is Catalyst Pharmaceuticals in the S&P 500?
  • Is Catalyst Pharmaceuticals in the NASDAQ 100?
  • Is Catalyst Pharmaceuticals in the Dow Jones?
  • When was Catalyst Pharmaceuticals's last earnings report?
  • When does Catalyst Pharmaceuticals report earnings?
  • Should I buy Catalyst Pharmaceuticals stock now?

What is the primary business of Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals (CPRX) is a biopharmaceutical company focused on developing and commercializing treatments for rare neurological diseases. They aim to improve the lives of patients with conditions like Lambert-Eaton Myasthenic Syndrome (LEMS) through innovative therapies and strong partnerships in the healthcare industry.

What is the ticker symbol for Catalyst Pharmaceuticals?

The ticker symbol for Catalyst Pharmaceuticals is NASDAQ:CPRX

Does Catalyst Pharmaceuticals pay dividends?

No, Catalyst Pharmaceuticals does not pay dividends

What sector is Catalyst Pharmaceuticals in?

Catalyst Pharmaceuticals is in the Healthcare sector

What industry is Catalyst Pharmaceuticals in?

Catalyst Pharmaceuticals is in the Biotechnology industry

What country is Catalyst Pharmaceuticals based in?

Catalyst Pharmaceuticals is headquartered in United States

When did Catalyst Pharmaceuticals go public?

Catalyst Pharmaceuticals's initial public offering (IPO) was on 08 November 2006

Is Catalyst Pharmaceuticals in the S&P 500?

No, Catalyst Pharmaceuticals is not included in the S&P 500 index

Is Catalyst Pharmaceuticals in the NASDAQ 100?

No, Catalyst Pharmaceuticals is not included in the NASDAQ 100 index

Is Catalyst Pharmaceuticals in the Dow Jones?

No, Catalyst Pharmaceuticals is not included in the Dow Jones index

When was Catalyst Pharmaceuticals's last earnings report?

Catalyst Pharmaceuticals's most recent earnings report was on 7 November 2024

When does Catalyst Pharmaceuticals report earnings?

The next expected earnings date for Catalyst Pharmaceuticals is 28 February 2025

Should I buy Catalyst Pharmaceuticals stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions